SYK - Stryker Corporation
| Previous Close | 172.90 |
| Open | 172.35 |
| Bid | 171.38 x 800 |
| Ask | 177.80 x 800 |
| Day's Range | 172.30 - 175.52 |
| 52 Week Range | 137.70 - 175.52 |
| Volume | 950,262 |
| Avg. Volume | 1,188,953 |
| Market Cap | 65.556B |
| Beta | 0.48 |
| PE Ratio (TTM) | 65.46 |
| EPS (TTM) | 2.68 |
| Earnings Date | Jul 25, 2018 - Jul 30, 2018 |
| Forward Dividend & Yield | 1.88 (1.11%) |
| Ex-Dividend Date | 2018-06-28 |
| 1y Target Est | 181.04 |
- Zacks•15 days ago
Zacks.com featured expert Kevin Matras highlights: Waste Connections, Roper, Stryker and Hi-Crush
Zacks.com featured expert Kevin Matras highlights: Waste Connections, Roper, Stryker and Hi-Crush
- GlobeNewswire•16 days ago
Consolidated Research: 2018 Summary Expectations for ONEOK, People's United Financial, Spirit Realty Capital, Stryker, Ultra Clean, and V.F. — Fundamental Analysis, Key Performance Indications
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ONEOK, ...
- Zacks•27 days ago
Stryker (SYK) Q1 Earnings Beat Estimates, 2018 View Solid
Stryker (SYK) gains from strong segmental show in Q1; a solid guidance is promising.
- Zacks•29 days ago
Medical Product Stock Earnings Roster for Apr 26: BAX & More
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
- Market Realist•last month
Will Boston Scientific Beat 1Q18 Earnings Estimates?
In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.
- Zacks•last month
Here's Why You Should Invest in Stryker (SYK) Right Now
Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.
- Zacks•last month
Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group
Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group
- Zacks•last month
4 MedTech Stocks to Keep in Good Books This Earnings Season
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
- Zacks•last month
7 Stocks With Impressive Sales Growth to Keep an Eye On
Sales growth is an important indicator of a company's health and its ability to sustain its business.
- Zacks•last month
Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.
- Zacks•last month
Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.
- Zacks•last month
Stryker Loses 7.6% in a Month: What's Weighing It Down?
Stryker's (SYK) declining margins and demand for healthcare products raise concern.
- Market Realist•2 months ago
Johnson & Johnson’s Business Segments in 2017
Analyzing Johnson & Johnson’s Stock and Valuations in March 2018
Market Realist•2 months agoAnalysts’ Recommendations on BD Stock in March 2018
BDX's March 2018 Performance, Recommendations, and UpdatesAnalysts’ latest recommendations
- Zacks•2 months ago
3D Printing in Vogue: 4 MedTech Stocks to Keep an Eye On
3D printing lends a competitive edge to medical device manufacturers by enhancing efficiency and cutting down on processing time.
- Market Realist•2 months ago
What Could Boost Haemonetics’ Revenues in Future Years
Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.
Market Realist•2 months agoHAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.
Market Realist•2 months agoPlasma Remains an Attractive Business for HAE
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
Market Realist•2 months agoPlasma Continues to Drive Strong Growth for HAE in Fiscal 2018
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
- Market Realist•2 months ago
HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018
On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.
Market Realist•2 months agoHAE Is Expected to Report Flat Revenue Performance in Fiscal 2018
Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.
- Zacks•2 months ago
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Market Realist•2 months agoWhy ConMed Is Expected to Report a Slight Rise in Its Net Profit Margin in 2018
ConMed (CNMD) expects to witness the positive impact of around 0.5–1.0 percentage points on its fiscal 2018 adjusted gross margin, attributable to various cost-saving initiatives. ConMed has also projected an improvement of ~0.2–0.5 percentage points in its ratio of SG&A (selling, general, and administrative) expenses to total sales for fiscal 2018 on a YoY (year-over-year) basis. ConMed also expects its 2018 R&D (research and development)-to-sales ratio to be at the higher end of the projected range of 4.5%–5%.
Market Realist•2 months agoWhy ConMed Is Expected to Report Robust Revenue Growth in 2018
ConMed (CNMD) expects to report revenue growth in the range of 5%–6.5% on a reported basis and in the range of 4.0%–5.0% on a CC (constant currency) basis for fiscal 2018. The company has projected a favorable top-line impact of 100–150 basis points, resulting from foreign exchange movements for fiscal 2018. In 2017, ConMed reported a ~4.3% YoY (year-over-year) rise in revenues on a CC basis, which would be in line with the average revenue growth in the medical technology industry.
